Antibodies are bringing in a good deal of money and CAT has brought in a fair amount of money, but will bring in a lot more because CAT has developed an antibody called Humira. It's called... as you know, it was made for a German firm, BASF who's going over to biologicals and Knoll, and this antibody is for rheumatoid arthritis. Now there are a lot of antibodies for rheumatoid arthritis. Now, what they do mostly is to stop the pain, but the Humira actually stops the progression of the disease. This was developed purely by CAT together with Greg, Greg was the scientific adviser, and this is a big blockbuster. It will be selling... it sells at the moment about 1.6 billion worth a year. It looks as though the sales next year will be 2 billion. Now that's a blockbuster drug, it isn't as big as some drugs, but it's bigger than almost all of them. But as I said, there's a court case where they refuse to pay the royalties. So after... so from then on, the MRC accepted equity, and we're going to set up companies, but before I set up the... before we set up CAT, I had to be... I had to break the tradition that all our discoveries went to Celltech, particularly in this field. So when I became Director, I had the support of... we were in the position, roughly in this position, CAT hadn't been established yet, and I found that a man at Headquarters was simply assigning any patent we took out to Celltech for no recompense, you see, non-whatever. The idea was this was part of British industry, would help British industry, and we were just backroom boys and shouldn't be involved in any of this. This was the way they looked upon it. In fact, I think... they didn't call us boffins, but that's the attitude they had, you know, we didn't know about the wider world of commerce and exploitation, and the Head of Celltech... so I began to try to get rid of our agreement with Celltech. This took a whole year, and I had the backing of César Milstein, who's Deputy Director, and of course, they'd made some monoclonal antibodies, but I was leaned on by MRC Headquarters, I was really literally leaned on, called in to MRC Headquarters and I resisted. I said, 'Well, I think we'll patent an antibody. We're not going to give them... we'll make the antibody and then we can patent', and things of that sort, and then we can do something with Celltech, trying to find ways of evasion. I was helped by Dai Rees who was the Head of the MRC elect, so he told me, 'Hang in there. When I become Head of the MRC, I'll support you.' So for a whole year... it was quite fun, with César Milstein who got very worried about the difference between winding up our relation with Celltech, and winding down our relationship, so we were... we decided to wind it down and eventually wind it up, and we did. So this was the brakes... this was now the MRC, this is beginnings of modern transfer... technology transfer.
